You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
福元醫藥(601089.SH):子公司藥品“傷濕止痛膏”、“消炎鎮痛膏”上市許可持有人變更申請獲批
格隆匯 09-16 16:08

格隆匯9月16日丨福元醫藥(601089.SH)公佈,公司下屬全資子公司福元藥業有限公司獲得國家藥品監督管理局核准簽發的“傷濕止痛膏”、“消炎鎮痛膏”《藥品補充申請批准通知書》,上述藥品上市許可持有人由內蒙古科爾沁藥業有限公司變更為福元藥業有限公司

傷濕止痛膏:該藥品主要適用於風濕性關節炎,肌肉疼痛,關節腫痛的治療。經查詢國家藥監局網站數據顯示,該藥品另有河南羚鋭製藥股份有限公司、雲南白藥集團股份有限公司等35家企業獲得上市批准。

該藥品為中藥貼膏,根據第三方數據庫米內網查詢顯示,該藥品2021年中國城市實體藥店銷售額約為1.7343億元。

消炎鎮痛膏:該藥品主要適用於神經痛,風濕痛,肩痛,扭傷,關節痛,肌肉疼痛的治療。經查詢國家藥監局網站數據顯示,該藥品另有河南羚鋭製藥股份有限公司、廣州白雲山醫藥集團股份有限公司等24家企業獲得上市批准。

該藥品為中藥貼膏,根據第三方數據庫米內網查詢顯示,該藥品2021年中國城市實體藥店銷售額約為3.1393億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account